The viewpoint of schizophrenic patients: A European survey;La parole aux patients schizophrènes: Enquête Eurpéenne

Encephale

Volumn 27, Issue 1, 2001, Pages 28-38

  Courtet, Ph ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

Atypical antipsychotics; Schizophrenia; Subjective feelings

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; HUMAN; PATIENT COMPLIANCE; SCHIZOPHRENIA; TREATMENT INDICATION;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; EUROPE; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PATIENT SATISFACTION; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SICK ROLE; TREATMENT OUTCOME;

EID: 0035079826     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Predicting medication compliance in a psychotic population
2. Non-compliance with treatment in patients suffering from schizophrenia: A study to evaluate possible contributing factors
3. Neuroleptiques atypiques et cognition
4. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
5. Subjective response to neuroleptics and the quality of life: Implications for treatment outcome
6. Subjective response to neuroleptics in schizophrenia
7. Factors influencing relapse in the long-term course of schizophrenia
8. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
9. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
10. Treatment adherence
11. La perception subjective de l'effet des neuroleptiques chez des patients schizophrènes ambulatoires: Une étude transversale
12. A two-year prospective study of treatment compliance in patients with schizophrenia
13. Patients' opinions concerning side effects of depot neuroleptics
14. Annonce du diagnostic, information sur la maladie et observance du traitement chez le sujet schizophrène
15. Que recouvre le terme 'stabilisation' des patients schizophrènes?
16. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
17. New antipsychotic medications: What advantages do they offer?
18. From noncompliance to collaboration in the treatment of schizophrenia
19. Awareness of illness in schizophrenia and outpatient treatment adherence
20. Les neuroleptiques: Nouvelles perspectives
21. Risperidone versus haloperidol: II. Cost-effectiveness
22. Olanzapine for schizophrenia
23. Technique for training schizophrenic patients in illness self-management: A controlled trial
24. Determinants of medication compliance in schizophrenia: Empirical and clinical findings
25. Conventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patients
26. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia
27. Formulary decisions and health economics
28. What are the functional consequences of neurocognitive deficits in schizophrenia?
29. Prescriptrion hospitalière de la rispéridone et de l'olanzapine: Enquête et recommandations
30. Functional outcomes in schizophrenia: A comparison of olanzapine and haloperidol in a European sample
31. Collaboration with drug treatment by schizophrenic patients with and without psychoeducational training: Results of a 1-year follow-up
32. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia
33. Compliance in psychoses
34. Compliance in the long-term treatment of schizophrenia
35. Problems of compliance in the outpatient treatment of schizophrenia
36. Screening for cognitive toxicity of anticholinergic drugs
37. Psychological predictors of insight and compliance in psychotic patients
38. Compliance therapy in psychotic patients: Randomised controlled trial
39. Effective resolution of acute presentation of behavioral agitation and positive symptoms in schizophrenia with olanzapine
40. Comparaison économique de l'olanzapine versus halopéridol dans le traitement de la schizophrénie en France
41. The development of treatment resistance in patients with schizophrenia: A clinical and pathophysiologic perspective
42. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis
43. Insight and adherence to medication in chronic schizophrenics
44. Wisconsin card sorting test and work performance in schizophrenia
45. Insight and cognitive impairment in schizophrenia. Performance on repeated administrations of the Wisconsin Card Sorting Test
46. Relationship between insight, educational background and cognition in schizophrenia
47. Risperidone in the treatment of schizophrenia
48. Clinical experience with risperidone
49. Facilitating compliance with antipsychotic medication
50. Common sense, insight, and neuropsychological test performance in schizophrenia patients
51. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
52. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment
53. Neuropsychologic deficits in schizophrenia: Relation to social function and effect of antipsychotic drug treatment
54. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables
55. Lack of insight: Its status within schizophrenic psychopathology
56. Adherence to antipsychotic medications
57. Nouvelles stratégies thérapeutiques dans la schizophrénie: À propos d'une décompensation aiguë traitée par olanzapine
58. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications
59. Compliance with treatment in schizophrenia: A drug intervention program in a developing country
60. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial
61. Medication continuation and compliance: A comparison of patients treated with clozapine and haloperidol
62. The costs of schizophrenia. Assessing the burden
63. Olanzapine versus haloperidol treatment in first-episode psychosis
64. Utilisation des nouveaux antipsychotiques dans le traitement de la schizophrénie - Une enquête européenne
65. Effect of patient education on medication compliance
66. The phenomenology of traumatic reactions to psychotic illness
67. Extrapyramidal symptoms in patients treated with risperidone
68. Schizophrenic and medical inpatients as informed drug consumers
69. Which atypical antipsychotic
70. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
71. Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol
72. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
73. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia
74. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
75. Subjective response to antipsychotic drugs
76. Drug refusal in schizophrenia: Causes and prescribing hints
77. The functional significance of symptomatology and cognitive function in schizophrenia
78. Rating of medication influences (ROMI) scale in schizophrenia
79. Is neuroleptic dysphoria a healthy response?
80. Neuroleptics and the natural course of schizophrenia
81. Medication noncompliance in schizophrenia: Codification and update
82. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia